Helsinki - Delayed Quote EUR

Orion Oyj (ORNAV.HE)

100.40 +1.60 (+1.62%)

At close: 6:29:56 PM GMT+2

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Orion Oyj (HLSE:ORNBV) Stock Richly Valued Despite Q3 Earnings Surge

Simply Wall St. 6d ago

ORNBV.HE

ORNAV.HE
+1.62%
Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline

GlobeNewswire 7d ago

271560.KS

ORNAV.HE
+1.62%
Is Orion Oyj (HLSE:ORNBV) Fully Priced On Phase 3 Darolutamide Trial News?

Simply Wall St. 9d ago

ORNBV.HE

ORNAV.HE
+1.62%
Changes in Orion Group’s Executive Team as of 1 January 2027

GlobeNewswire 9d ago

271560.KS

ORNAV.HE
+1.62%
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

GlobeNewswire 11d ago

ORNAV.HE
+1.62%
Inside information: Orion upgrades full-year outlook for 2026

GlobeNewswire 15d ago

271560.KS

ORNAV.HE
+1.62%
Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026

GlobeNewswire 21d ago

271560.KS

ORNAV.HE
+1.62%
125,000 Orion Corporation A shares converted into B shares

GlobeNewswire 28d ago

ORNAV.HE
+1.62%
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market

GlobeNewswire 29d ago

271560.KS

ORNAV.HE
+1.62%
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing

GlobeNewswire 30d ago

271560.KS

ORNAV.HE
+1.62%
Orion Corporation completed share acquisitions

GlobeNewswire 1mo ago

271560.KS

ORNAV.HE
+1.62%
Orion Corporation: Acquisition of own shares during week 40, 2026

GlobeNewswire 1mo ago

271560.KS

ORNAV.HE
+1.62%

Performance Overview

Return	ORNAV.HE	OMX Helsinki_PI (^OMXHPI)
YTD	+62.44%	--
1-Year	+71.09%	--
3-Year	+199.80%	--

U.S. markets closed

Orion Oyj (ORNAV.HE)

Orion Oyj (HLSE:ORNBV) Stock Richly Valued Despite Q3 Earnings Surge

Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline

Is Orion Oyj (HLSE:ORNBV) Fully Priced On Phase 3 Darolutamide Trial News?

Changes in Orion Group’s Executive Team as of 1 January 2027

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Inside information: Orion upgrades full-year outlook for 2026

Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026

125,000 Orion Corporation A shares converted into B shares

Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing

Orion Corporation completed share acquisitions

Orion Corporation: Acquisition of own shares during week 40, 2026